Arin戰術極端風險主動型ETF ATTR 深 滬
等待開盤 03-26 09:30:00 美东时间
90.9727
+0.175
+0.19%
華盛通- 最 高91.16
- 今 開91.16
- 成交量 250股
- 最 低 90.9727
- 昨 收 90.7978
- 總市值 8998.11万
- 52周最高 91.56
- 市盈率 靜 --
- 換手率 0.03%
- 52周最低 88.71
- 委 比 0.00%
- 總股本 98.91万
- 歷史最高 91.56
- 量 比 0.31
- 振 幅 0.21%
- 歷史最低 88.71
- 每 手 1
- 風險率 0.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BridgeBio Pharma To Share Long-Term Efficacy, Safety Data In Participants With ATTR-CM From Its Phase 3 Trial Of Acoramidis At American College of Cardiology Annual Scientific Sessions & Expo
BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that long-term efficacy and safety data in
03-23 19:37
Arbutus Biopharma FY 2025 net loss was USD 34 million, revenue rose 128% to USD 14 million
Arbutus Biopharma FY 2025 net loss was USD 34 million, revenue rose 128% to USD 14 million Arbutus published a fourth-quarter and full-year 2025 earnings release, reporting FY revenue of USD 14.1 million and a FY net loss of USD 33.5 million, or USD 0.17 per share. FY revenue rose 128% to USD 14.1 m
03-23 19:31
BridgeBio to present long-term ATTRibute-CM open-label extension data on acoramidis at ACC 2026
BridgeBio to present long-term ATTRibute-CM open-label extension data on acoramidis at ACC 2026 BridgeBio reported that long-term efficacy and safety data from the open-label extension (OLE) of its Phase 3 ATTRibute-CM trial of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-C
03-23 19:31
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory filings and potential commercial launches.
03-11 02:49
BRIEF-Spirit Airlines To Recall Furloughed Pilots To Combat Attrition As Carrier Eyes Bankruptcy Exit - CNBC
BRIEF-Spirit Airlines To Recall Furloughed Pilots To Combat Attrition As Carrier Eyes Bankruptcy Exit - CNBC March 10 (Reuters) - SPIRIT AIRLINES TO RECALL FURLOUGHED PILOTS TO COMBAT ATTRITION AS CARRIER EYES BANKRUPTCY EXIT - CNBC Source text: https://tinyurl.com/3bwhbk2s Further company coverage:
03-10 20:15
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments March 5 (Reuters) - Tenaya Therapeutics TNYA.O said on Thursday it has signed a research deal with Alnylam Pharmaceuticals ALNY.O worth up to $1.13 billion to develop treatments for heart diseases. Shares of Tenaya
03-05 22:08
Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial
Intellia shares climb after FDA lifts hold on MAGNITUDE trial, clearing path to resume late-stage study of nex-z treatment.
03-02 23:05
Alnylam Canada ULC Wins CDA Reimbursement Recommendation For AMVUTTRA In ATTR Cardiomyopathy
Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025,
03-02 21:14
BRIEF-JP Morgan Raises 3Q TTF Gas Price Forecast To 27 EUR/Mwh From 25 EUR/Mwh
BRIEF-JP Morgan Raises 3Q TTF Gas Price Forecast To 27 EUR/Mwh From 25 EUR/Mwh Feb 27 (Reuters) - JP MORGAN: SAYS IT IS INCREASING 3Q TTF GAS PRICE FORECAST TO 27 EUR/MWH FROM 25 EUR/MWH SAYS IT IS INCREASING 4Q26-1Q27 TTF GAS PRICE FORECAST TO 30 EUR/MWH FROM 27 EUR/MWH SAYS EUROPEAN GAS STORAGE RE
02-27 14:11
JP MORGAN: INCREASING OUR 4Q26-1Q27 TTF GAS PRICE FORECAST TO 30 EUR/MWH FROM 27 EUR/MWH
BRIEF-JP Morgan Raises 3Q TTF Gas Price Forecast To 27 EUR/Mwh From 25 EUR/Mwh Feb 27 (Reuters) - JP MORGAN: SAYS IT IS INCREASING 3Q TTF GAS PRICE FORECAST TO 27 EUR/MWH FROM 25 EUR/MWH SAYS IT IS INCREASING 4Q26-1Q27 TTF GAS PRICE FORECAST TO 30 EUR/MWH FROM 27 EUR/MWH SAYS EUROPEAN GAS STORAGE RE
02-27 14:02
